Monomethyl fumarate treatment impairs maturation of human myeloid dendritic cells and their ability to activate T cells

Dimethyl fumarate (DMF) and its active metabolite monomethyl fumarate (MMF) effectively lead to reduction in disease relapses and active magnetic resonance imaging (MRI) lesions. DMF and MMF are known to be effective in modulating T- and B-cell responses; however, their effect on the phenotype and f...

Celý popis

Podrobná bibliografie

Vydáno v:	Multiple sclerosis Ročník 25; číslo 1; s. 63
Hlavní autoři:	Mazzola, Maria Antonietta, Raheja, Radhika, Regev, Keren, Beynon, Vanessa, von Glehn, Felipe, Paul, Anu, Pierre, Isabelle, Kivisakk, Pia, Weiner, Howard L, Gandhi, Roopali
Médium:	Journal Article
Jazyk:	angličtina
Vydáno:	England 01.01.2019
Témata:	Dendritic Cells - drug effects Dimethyl Fumarate - pharmacology Fumarates - pharmacology Humans Immunologic Factors - pharmacology Multiple Sclerosis, Relapsing-Remitting - blood Multiple Sclerosis, Relapsing-Remitting - drug therapy Myeloid Cells - drug effects T-Lymphocytes - drug effects co-stimulatory molecules Multiple sclerosis dimethyl fumarate myeloid dendritic cells monomethyl fumarate NF-kB
ISSN:	1477-0970, 1477-0970
On-line přístup:	Zjistit podrobnosti o přístupu
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!